Showing 1741-1750 of 7669 results for "".
- Merz Makes Offer for Obagihttps://practicaldermatology.com/news/20130402-merz_makes_offer_for_obagi/2459576/With an unexpected $383.5 million bid, Merz Pharma Group formally proposed to acquire Obagi Medical Products, outdoing rival Valeant's bid for Obagi announced late last month and reported in yesterday's edition of DermWire. Merz sent a letter to Obagi Medical Products Inc.'s board offering to buy a…
- New Survey Finds Social Media is a Major Influence on Elective Surgeryhttps://practicaldermatology.com/news/20130327-new_survey_finds_social_media_is_a_major_influence_on_elective_surgery/2459578/Social media is leading consumers to have a more self-critical eye, according to a new survey by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). The annual poll of the organization's board-certified facial plastic surgeons found a 31 percent increase in requests for surg…
- Merz to Absorb Costs of New Excise Tax on Certain Medical Deviceshttps://practicaldermatology.com/news/20130321-merz_to_absord_costs_of_new_excise_tax_on_medical_devices/2459580/Merz Aesthetics announced that it does not intend to raise prices on medical devices, despite the new excise tax on the sale of certain medical devices of about 2.3 percent now going into effect, per the Patient Protection and Affordable Care Act. In a statement to clients and potential clients, Me…
- Valeant Pharmaceuticals to Acquire Obagi Medical Products for Approximately $344 Millionhttps://practicaldermatology.com/news/20130320-valeant_pharmaceuticals_to_acquire_obagi_medical_products_for_approximately_360_million/2459581/Valeant Pharmaceuticals has entered into an agreement to acquire Obagi Medical Products. The transaction values Obagi common stock at approximately $344 million and was unanimously approved by the Obagi Board of Directors. Under terms of the merger agreement, Valeant will commence a tender offer fo…
- Investigational Melanoma Agent Meets Endpoint in Phase 3 Trialhttps://practicaldermatology.com/news/20130320-investigational_melanoma_agent_meets_endpoint_in_phase_3_trial/2459582/New Phase 3 trial data found that Amgen's investigational melanoma agent talimogene laherparepvec met its primary endpoint of durable response rate for the treatment of unresected stage IIIB, IIIC, or IV melanoma. Researchers observed a statistically significant difference of 16 percent in DRR in p…
- District Court Judge Blocks Marketing and Sales of RevitaLashhttps://practicaldermatology.com/news/20130320-district_court_judge_blocks_marketing_and_sales_of_revitalash/2459584/A district court judge recently prohibited Athena Cosmetics, Inc. from marketing or selling its RevitaLash Advanced Eyelash Conditioner in the United States. The ruling came as part of a civil lawsuit brought by Allergan Inc., maker of Latisse, in which the company claimed unfair competition in the…
- On Match Day, AMA Calls for Additional Residency Positions to Address Physician Shortagehttps://practicaldermatology.com/news/20130319-on_match_day_ama_calls_for_additional_residency_positions_to_address_physician_shortage/2459585/A statement released by Jeremy A. Lazarus, M.D., President of the American Medical Association, is seeking to raise awareness about the physician shortage. "Today, on Match Day, thousands of medical students will learn where they will complete their graduate medical education (GME), known as resid…
- Survey: Scars and Stretch Marks Significantly Impact Women's Confidencehttps://practicaldermatology.com/news/20130318-survey_scarsstretch_marks_have_significant_negative_impact_womens_confidence/2459586/A new survey reveals that men and women have complex and often differing feelings about how their skin Imperfections impact their appearance and confidence. In the Mederma® Wear Your Skin Proudly™ survey, 34 percent of women reported that the appearance of scar(s) and/or stretch marks would make th…
- Envy Medical Unveils New Acne Systemhttps://practicaldermatology.com/news/20130311-envy_medical_unveils_new_acne_system/2459595/Envy Medical Inc. recently launched the ClarityMD Acne Solution at the American Academy of Dermatology Annual Meeting on March 1 in Miami. The system includes a Deep Pore Cleanser and Clarifying Gel in a two-step system that's clinically proven to significantly heal acne within days, according to t…
- Naftifine Gel Found Effective for Moccasin-Type Tinea Pedishttps://practicaldermatology.com/news/20130307-naftifine_gel_found_effective_for_moccasin-type_tinea_pedis/2459600/New data has found that the topical antifungal agent naftifine hydrochloride gel 2% (Merz North America) is both efficacious and tolerable in the treatment for interdigital-type and moccasin-type Tinea pedis. In a poster presented at the AAD Annual Meeting in Miami, the authored sounds that naftifi…